Keywords: Uveitis; Drug induced uveitis; Posterior uveitis; Nivolumab; Anti-PD1; Chemotherapy; Check point inhibitors;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
Keywords: BM; brain metastasis; AE; adverse event; CI; confidence interval; CTLA4; cytotoxic T-lymphocyte antigen-4; CT; computed-tomography; GPA; Graded Prognostic Assessment score; IORR; intracerebral objective response rate; IQR; interquartile range; NSCLC; nonâ
Keywords: Renal cell carcinoma; European Association of Urology guidelines; Nivolumab; Ipilimumab;
Keywords: Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Autoimmunity; Rheumatic manifestations; Psoriatic arthritis; Rheumatoid arthritis; Eosinophilic fasciitis; Sarcoidosis;
Keywords: Thyroiditis; PD-1; CTLA-4; Ipilimumab; Nivolumab; Cytology;
Keywords: PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un
Keywords: Urothelial carcinoma; Immune-checkpoint inhibitors; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab; Nivolumab; Ipilimumab; Combination therapy;
Keywords: Human Herpesvirus 6; Nivolumab; Immunotherapy; Lung cancer;
Keywords: Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab;
Keywords: Chemotherapy; Oral cancer; Chemoradiation; Cisplatin; Cetuximab; Nivolumab; Pembrolizumab;
Keywords: Anti-Hu antibody; Limbic encephalitis; Nivolumab;
Keywords: Cabozantinib; Disease-free survival; Network meta-analysis; Nivolumab; Renal cell carcinoma;
Keywords: 5-fluorouracil; imiquimod; ingenol mebutate; acitretin; American Joint Commission on Cancer; Brigham and Women's Hospital staging system; capecitabine; CDKN2A; cetuximab; chemotherapy; classification; cSCC; CT; cutaneous squamous cell carcinoma; familial
Keywords: Pancytopenia; Lung cancer; Immune checkpoint inhibitor; Nivolumab; Immune related adverse event;
Keywords: Melanoma; Adjuvant treatment; Nivolumab; Pembrolizumab; Target therapy; New strategies;
Keywords: Clinical outcome; Radiofrequency ablation; Hepatocellular carcinoma; Alpha-fetoprotein; microRNAs; PD-L1; Nivolumab; Tremelimumab; Immunotherapy; Circulating miRNAs;
Keywords: Renal cell carcinoma; Cabozantinib; Nivolumab; Ipilimumab; Bevacizumab; Atezolizumab;
Keywords: programmed cell death 1; immunohistochemistry; harmonization; nivolumab;
Keywords: Checkpoint immunotherapy; CTLA-4, PD-1; Ipilimumab; Nivolumab; Neuropathy; Guillain-Barre;
Keywords: Nivolumab; NSCLC; SCLC transformation; Immune checkpoint inhibitor;
Keywords: ICIs; immune checkpoint inhibitors; irAEs; immune-related adverse events; NK-1R; neurokinin-1 receptor; NSCLC; non-small-cell lung cancer; SJS; Stevens-Johnson syndrome; immune checkpoint inhibitors; immune-related adverse events; nivolumab; Stevens-Johns
Keywords: Nivolumab; Non-small-cell lung cancer; Immune-related adverse event; Hu paraneoplastic antibody; Neurological toxicity; Dysphasia;
Keywords: Immune checkpoint inhibitors; Programmed cell death-protein 1; Nivolumab; Uveitis; Melanoma;
Keywords: Androgen deprivation therapy; Castrate resistant; Immunotherapy; Nivolumab; Prostate cancer;
Keywords: immune checkpoint blockade; ipilimumab; nivolumab; squamous cell carcinoma; cSCC; cutaneous squamous cell carcinoma; DICB; dual immune checkpoint blockade; ICB; immune checkpoint blockade; ipi/nivo; ipilimumab and nivolumab; mcSCC; metastatic cSCC;
Keywords: Brentuximab vedotin; checkpoint inhibitors; nivolumab; pembrolizumab; transplant;
Keywords: Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events;
Keywords: NSCLC; Immunotherapy; Adenocarcinoma; Nivolumab; Colitis; Pneumonitis; Pericarditis;
Keywords: Immune-related adverse event; Immunotherapy; Nivolumab; Non-small cell lung cancer; Psoriatic arthritis; Programmed cell death-1;
Keywords: Immunotherapy; Pembrolizumab; Nivolumab; First-line; Non-small cell lung cancer;
Keywords: Nivolumab; Non-small cell lung cancer; Neutrophil-to-lymphocyte ratio; PD-1; Immunotherapy;
Keywords: Immune-related adverse events; Hypophysitis; Thyroiditis; Ipilimumab; Nivolumab; Melanoma;
Keywords: anti-programmed cell death-1 therapy; nivolumab; pembrolizumab; vitiligo; vitiligo-like lesions; Abs; antibodies; CXCL; C-X-C motif ligand; CXCR; C-X-C motif receptor; IFN; interferon; IL; interleukin; PD; programmed cell death; TNF; tumor necrosis fact
Keywords: Mismatch repair deficiency; Lynch syndrome; Immune checkpoint; Nivolumab; Endometrial cancer; Colorectal cancer; Cancer de l'endomètre; Cancer colorectal; Checkpoint immunitaires; Déficience du système de réparation de l'ADN; Nivolumab; Syndrome d
Keywords: cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: Atezolizumab; ipilimumab; nivolumab; pembrolizumab; treatment-related death; tremelimumab;
Keywords: Immune checkpoint; Immunotherapy; Programmed death-1; Cytotoxic T lymphocyte associated protein â4; Pembrolizumab; Nivolumab;
Keywords: Atezolizumab; Chemotherapy; Docetaxel; Nivolumab; Pembrolizumab;
Keywords: Collecting duct carcinoma; Metastatic renal cell carcinoma; Nivolumab; Non-clear cell renal cell carcinoma; PD1 inhibitor;
Keywords: Nivolumab; Non-small-cell-lung cancer; Programmed death 1; Immune thrombocytopenia; Immune-related adverse events;
Keywords: Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Organ transplantation; Rejection;
Keywords: Programmed cell death 1; PD-1; PDCD1; anti-PD-1 antibody; PD-1 inhibitor; nivolumab; pembrolizumab; acute interstitial nephritis (AIN); acute kidney injury (AKI); non-small cell lung cancer (NSCLC); advanced melanoma; ipilimumab; immune checkpoint inhib
Keywords: Anti-PD-1 antibody; Immunotherapy; Nivolumab; PD-L1; Second-line treatment;
Keywords: Biomarkers; Sipuleucel-T; Ipilimumab; Nivolumab; Ki-67; MDSCs; Tregs; ELISpot; Renal cell; Prostate cancer; Bladder cancer; CTCs; PSA; PSMA; IL-2; Immunoscore; Cytokines
Keywords: acute kidney injury; ipilimumab; nivolumab; pembrolizumab;
Keywords: Immune-checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Nivolumab; Pembrolizumab; Melanoma; Lung cancer; Renal cancer
Keywords: PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab
Keywords: Fatigue; ipilimumab; nivolumab; pembrolizumab; tremelimumab;